The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > BUSINESS
BUSINESS
- Kowa Seeks Japan Approval of Livalo Successor Pemafibrate
October 20, 2015
- Daiichi Sankyo to Shed 1,000 Jobs in US
October 20, 2015
- Shift to Specialty - 1: Drug Makers Urged to Retool Strategies amid Govt Pressure, Dismal Biz Environment
October 19, 2015
- Eisai, Ajinomoto Link Arms to Create Leading Specialty Pharma for GI Disease
October 16, 2015
- MSD Files Allergy Drug Desloratadine in Japan
October 16, 2015
- Eisai’s GI Disease Biz to Integrate with Ajinomoto Pharma
October 15, 2015
- Plavix Retains Top Slot in FY2014 Japan Drug Sales Ranking: Jiho Tally
October 14, 2015
- Toyama Chemical Licenses RA Drug to Turkish Firm
October 14, 2015
- Astellas Gains Worldwide Rights to Next-Gen DNA Vaccines
October 13, 2015
- (PRESS RELEASE) Shionogi to Spin Off Consumer Healthcare Biz Next Year
October 13, 2015
- Eisai’s Thyroid Cancer Drug Lenvima Approved in S. Korea
October 13, 2015
- AZ Begins Japan PI Trial of CTLA-4 Inhibitor for Malignant Mesothelioma
October 9, 2015
- Ethical Drug Sales Surge 9.0% in August: Crecon Report
October 8, 2015
- Meiji Seika Pharma Commences Long-Term Studies of Safinamide
October 8, 2015
- Merck Lauds Nobel Medicine Prize Winners Omura, Campbell
October 7, 2015
- GreenPeptide Files IND in US for Cancer Peptide Vaccine
October 7, 2015
- Anti-Obesity Effect of Rare Sugar D-Psicose Confirmed: Matsutani Chemical Industry
October 7, 2015
- Eisai Offers Indonesia 151 Million Tablets of Elephantiasis Drug for Free
October 6, 2015
- GSK to Seek COPD Indication for Relvar in January-March 2016
October 6, 2015
- Belsomra Most Heavily Pitched Drug in July: Anterio Ranking
October 5, 2015
ページ
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…